Literature DB >> 6992059

The growth of Trypanosoma cruzi in human diploid cells for the production of trypomastigotes.

C J Sanderson, J A Thomas, C E Twomey.   

Abstract

The use of human diploid cell lines of finite life for the in vitro production of Trypanosoma cruzi is described. Both MRC5 and WI38 cells release trypomastigotes with less than 5% amastigotes. This could form the basis for biochemical and immunological studies, which were previously limited by the problems of separating parasites from blood. By selecting the in vitro passage number of the parasite it is possible to select for either the broad or the slender forms of trypomastigotes, allowing comparative studies of these forms within a single strain of the parasite. It is also possible to isolate amastigotes by disrupting the cells before trypomastigotes appear, and separating them from cell debris with Metrizamide. It is shown that by incorporating [3H]uridine in the cell-culture medium, labelled trypomastigotes are obtained. The release of this label (putative RNA) provides a relatively simple isotopic assay for parasite death. Examples of this assay for testing drug toxicity and in immunological lysis are presented.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992059     DOI: 10.1017/s0031182000000615

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  14 in total

1.  Variation in antigenic determinants specific to the infective stage of Trypanosoma cruzi.

Authors:  R A Wrightsman; W Leon; J E Manning
Journal:  Infect Immun       Date:  1986-08       Impact factor: 3.441

2.  Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance.

Authors:  K A Norris
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Enhancement of macrophage microbicidal activity: supplemental arginine and citrulline augment nitric oxide production in murine peritoneal macrophages and promote intracellular killing of Trypanosoma cruzi.

Authors:  K A Norris; J E Schrimpf; J L Flynn; S M Morris
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

4.  Isolation and purification of amastigotes of Trypanosoma cruzi from cultured vero cells.

Authors:  F Gamarro; A Osuna; S Castanys; M I Pérez-López; L M Ruiz-Pérez
Journal:  Z Parasitenkd       Date:  1985

5.  Genomic variation of Trypanosoma cruzi: involvement of multicopy genes.

Authors:  W Wagner; M So
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies.

Authors:  K A Norris; G Harth; M So
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

7.  Characterization of glucose transport and cloning of a hexose transporter gene in Trypanosoma cruzi.

Authors:  E Tetaud; F Bringaud; S Chabas; M P Barrett; T Baltz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

8.  Effect of allopurinol on Trypanosoma cruzi: metabolism and biological activity in intracellular and bloodstream forms.

Authors:  R L Berens; J J Marr; F S Steele da Cruz; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

9.  Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi.

Authors:  K A Norris; J E Schrimpf
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection.

Authors:  M S Martins; L Hudson; A U Krettli; J R Cançado; Z Brener
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.